[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infant-nutrition-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infant-nutrition-disorders":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100385104","targeted-fortification-of-donor-breast-milk-in-preterm-infants-100385104",false,"NCT04294368","Targeted Fortification of Donor Breast Milk in Preterm Infants","Inclusion Criteria:\n\n* Premature infants born \\\u003C\u002F= 30 weeks gestational age\n* Birth Weight \\\u003C\u002F= 1500 grams\n\nExclusion Criteria:\n\n* Parents do no consent to donor milk\n* Confounders for poor growth such as congenital heart disease, GI diagnoses such as gastroschisis and omphalocele, and or major congenital anomalies\n* Grade III or IV intraventricular hemorrhage diagnoses prior to randomization\n* Small for gestational age (\\\u003C3% on Fenton Growth Curve)\n* Failure to initiate fortified feeds prior to 3 weeks of life\n* Diagnosis of necrotizing entercolitis prior to randomization\n* Diagnosis of early onset sepsis confirmed with positive culture","ALL","1 Day","21 Days",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The investigators hypothesize that infants receiving targeted fortification of donor breast milk will have improved growth compared to infants receiving standard fortification of donor breast milk.",[26,27,28,29,30],"Prematurity; Extreme","Failure to Thrive in Newborn","Growth Retardation","Growth Failure","Infant Nutrition Disorders",[32,33,34,35,36],"Human Milk Analyzer","Miris","Target Fortification","Targeted Fortification","Donor Breast Milk","RECRUITING","2026-04-01",{"date":40,"type":41},"2026-04-07","ACTUAL",{"date":43,"type":41},"2020-03-09",{"date":45,"type":20},"2027-03",{"name":47,"class":48},"Columbia University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100619284","smash-study-to-evaluate-the-clinical-efficacy-of-an-extensively-hydrolysed-infant-formula-with-synbiotics-and-a-human-milk-oligosaccharide-hmo-in-infants-with-cows-milk-protein-allergy-cmpa-100619284","NCT07342621","SMASH: Study to Evaluate the Clinical Efficacy of an Extensively Hydrolysed Infant Formula With Synbiotics and a Human Milk Oligosaccharide (HMO) in Infants With Cow's Milk Protein Allergy (CMPA)","SMASH","Inclusion Criteria:\n\n* Infants under 10 months of age at study start (Visit 1).\n* Suspected or recently confirmed cow's milk protein allergy (CMPA), as determined by the investigator.\n* Already formula-fed, or parents\u002Flegal guardians have decided to initiate formula feeding.\n* Inclusion in the study coincides with the first prescription of a hypoallergenic formula.\n* Written informed consent obtained from parents or legal guardians in accordance with local regulations.\n\nExclusion Criteria:\n\n* Infants with functional gastrointestinal symptoms in whom atopy or food allergy is not suspected.\n* Infants who have previously used an extensively hydrolyzed formula (EHF), an amino acid-based formula (AAF), a rice hydrolysate formula, or a soy-based formula.\n* Infants who have previously used a partially hydrolyzed formula for the prevention of cow's milk protein allergy (CMPA).\n* Infants for whom an amino acid-based formula (AAF) is more appropriate as first-line management, including severe forms of CMPA.\n* Contraindications to the use of synbiotics (e.g., preterm infants \\\u003C40 weeks of corrected gestational age at study start, immunodeficiency, short bowel syndrome, parenteral nutrition, post-pyloric feeding, central venous catheter, oncology treatment, or graft-versus-host disease).\n* Any other condition, as assessed by the investigator, that contraindicates the use of an extensively hydrolyzed formula.\n* Any other circumstance, as assessed by the investigator, indicating that the parents or legal guardians are not capable of complying with the study procedures.","10 Months",{"count":59,"type":20},41,"4 Weeks","OBSERVATIONAL","Cow's milk protein allergy (CMPA) is one of the most common food allergies in infants, with an estimated prevalence between 2% and 5%. The number of diagnosed cases has increased in recent years, with clinical manifestations involving the gastrointestinal tract, respiratory system, skin, or systemic reactions. Dietary elimination of cow's milk protein remains the mainstay of treatment, using extensively hydrolyzed formulas (EHF) or amino acid-based formulas (AAF), depending on the severity of the allergy.\n\nThis study aims to evaluate the clinical effect, as reported by physicians, of an extensively hydrolyzed whey-based formula (Almirón Pepti Syneo®) containing a symbiotic mixture (scGOS\u002FlcFOS 9:1 and Bifidobacterium breve M-16V), the human milk oligosaccharide 2'-fucosyllactose (2'-FL), and a reduced amount of purified lactose, in infants with suspected or confirmed CMPA in a real-world clinical practice setting.\n\nThis is a prospective, longitudinal, open-label, single-arm, multicenter study including approximately 41 infants under 10 months of age at several primary care centers and one hospital in Valencia, Spain. Each participant will be followed for four weeks. A subgroup of participants will also provide stool samples to explore the effect of the study formula on gut microbiota composition.",[64,65,30,66],"Cow's Milk Protein Allergy (CMPA)","Food Hypersensitivity","Gut Microbiota",[68,69,70,71,72,73],"Extensively Hydrolyzed Formula","Synbiotics","Cow's Milk Protein Allergy","Real World Evidence","Microbiota","Gastrointestinal Symptoms","2026-01-05",{"date":76,"type":41},"2026-01-15",{"date":78,"type":41},"2025-02-07",{"date":80,"type":20},"2026-04",{"name":82,"class":83},"Outcomes'10","NETWORK",13]